Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 5/20 | 0.50 |
| ▸ | CDK2 | P24941 | 4/20 | 0.50 |
| ▸ | CNR1 | P21554 | 4/20 | 0.44 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.41 |
| ▸ | AURKA | O14965 | 1/20 | 0.41 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.41 |
| ▸ | PSD | A5PKW4 | 1/20 | 0.40 |
| ▸ | ABL1 | P00519 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | RET | P07949 | 1/20 | 0.39 |
| ▸ | KDR | P35968 | 1/20 | 0.39 |
| ▸ | IDH1 | O75874 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14607199 | 0.94 | CDK2 (0.51) | GSK3BCDK2EPHB4AURKARPS6KB1 | |
| SCHEMBL14545901 | 0.93 | CDK2 (0.55) | GSK3BCDK2CNR1EPHB4PSD | |
| SCHEMBL14301776 | 0.91 | CDK2 (0.51) | GSK3BCDK2CNR1EPHB4AURKA | |
| SCHEMBL13121763 | 0.90 | CDK2 (0.64) | GSK3BCDK2 | |
| SCHEMBL14545278 | 0.89 | CDK2 (0.47) | GSK3BCDK2AURKARPS6KB1ABL1 | |
| SCHEMBL14607200 | 0.89 | CDK2 (0.49) | GSK3BCDK2CNR1MAPTRET | |
| SCHEMBL13289245 | 0.88 | CDK2 (0.49) | GSK3BCDK2EPHB4AURKARET | |
| SCHEMBL14301780 | 0.87 | CDK2 (0.47) | GSK3BCDK2KDR | |
| SCHEMBL13121743 | 0.87 | CDK2 (0.62) | GSK3BCDK2KDR | |
| SCHEMBL14607101 | 0.87 | GSK3B (0.50) | GSK3BCDK2ABL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2194058-A1 | Pyrazolopyrimidines suitable for the treatment of cancer diseases | SCHERING CORPORATION (US) | 2010-06-09 | — | — | EP | disclosed |